GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00. Gordon CFA covers the Healthc...

Barclays Remains a Sell on GlaxoSmithKline (GSK)

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK disclosed that non-executive director Dr. Hal Barron acquired American Depositary ...

GSK Discloses Routine ADS Purchase by Non-Executive Director Hal Barron

GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK has disclosed a series of routine insider transactions involving senior leadership, i...

GSK Executives Add Notional ADS Through Dividend Reinvestment Plan

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK’s latest hepatitis B update centers on its Phase 3 trial “Phase 3 M...

GSK Nears Key Hepatitis B Milestone With Completion of B-Well 1 Phase 3 Trial

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The Phase 3 B-Well 2 trial from GlaxoSmithKline tests bepirovirsen in p...

GSK’s B-Well 2 Hepatitis B Trial Reaches Completion, Setting the Stage for Key Data

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has disclosed a series of routine share dealings by senior executives under its ...

GSK executives acquire shares under company reward plan

GlaxoSmithKline ( ($GB:GSK) ) has provided an update. GSK disclosed that Maya Martinez-Davis, its President for the US, acquired a small number of ...

GSK Reports Executive Notional ADS Acquisition Under Savings Plan

GlaxoSmithKline ( ($GB:GSK) ) has issued an announcement. GSK reported that all 25 resolutions at its 26th Annual General Meeting, held as a hybrid...

GSK Wins Strong Shareholder Backing at 26th Annual General Meeting

In a report released today, Emmanuel Papadakis from Deutsche Bank reiterated a Hold rating on GlaxoSmithKline, with a price target of p1,900.00. Ac...

Deutsche Bank  Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

The latest update is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has granted a notional Ordinary Share award to Roanne Parry under its Deferred Inv...

GSK grants long-term deferred award to new Chief People Officer

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that its issued share capital as of 30 April 2026 stands at 4,316,202,660 ord...

GSK Updates Market on Total Voting Rights and Share Capital

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline on April 29 and set a price target of p1,500.00. The company’s share...

Kepler Capital  Remains a Hold on GlaxoSmithKline (GSK)

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline today and set a price target of £18.70. Sharma covers the Healthcare...

Goldman Sachs Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Here’s a quick look at today’s key earnings reports from major publicly traded companies. Investors will be watching closely for updates on financi...

These Are the Stocks Reporting Earnings Today – April 29, 2026

Deutsche Bank  Remains a Hold on GlaxoSmithKline (GSK)

The latest announcement is out from GlaxoSmithKline ( ($GB:GSK) ). GSK has confirmed the vesting of a conditional share award granted in 2023 to Ch...

Current Quarter	$1.28	Next Quarter	$1.47
Current Year	$4.87	Next Year	$5.13
QoQ Growth	+14.8%	YoY Growth	+5.3%
3Y EPS CAGR	+0.0%	Target Price	$56.57
Consensus	Buy	Upside	+9.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$51.74	+0.70%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$51.74	+0.7%	1.45M
3
4
5
6

GSK

GSK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel